Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 288

1.

Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.

Shimoni A, Gajewski JA, Donato M, Martin T, O'Brien S, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt S.

Biol Blood Marrow Transplant. 2001;7(10):568-75.

PMID:
11760089
[PubMed - indexed for MEDLINE]
2.

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J.

Blood. 1998 May 15;91(10):3671-80.

PMID:
9573003
[PubMed - indexed for MEDLINE]
Free Article
3.

T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.

Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA.

Blood. 1999 Jul 15;94(2):434-41. Erratum in: Blood 2000 Feb 15;95(4):1137.

PMID:
10397710
[PubMed - indexed for MEDLINE]
Free Article
4.

CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.

Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondón G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Körbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R.

Blood. 1995 Dec 1;86(11):4337-43.

PMID:
7492795
[PubMed - indexed for MEDLINE]
Free Article
5.

Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.

Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.

Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12.

PMID:
14993886
[PubMed - indexed for MEDLINE]
6.

Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy.

Novitzky N, Rubinstein R, Hallett JM, du Toit CE, Thomas VL.

Transplantation. 2000 Apr 15;69(7):1358-63.

PMID:
10798754
[PubMed - indexed for MEDLINE]
7.

Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.

Sehn LH, Alyea EP, Weller E, Canning C, Lee S, Ritz J, Antin JH, Soiffer RJ.

J Clin Oncol. 1999 Feb;17(2):561-8.

PMID:
10080600
[PubMed - indexed for MEDLINE]
Free Article
8.

Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.

Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR.

Blood. 1995 Nov 15;86(10):3987-96.

PMID:
7579370
[PubMed - indexed for MEDLINE]
Free Article
9.

Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.

Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ.

Biol Blood Marrow Transplant. 2006 Apr;12(4):414-21.

PMID:
16545725
[PubMed - indexed for MEDLINE]
10.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
[PubMed - indexed for MEDLINE]
11.

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.

Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, Moreno-Lafont M, García-Latorre E, Ramírez-Sanjuan E, Montiel-Cervantes L, Tripp-Villanueva F, García-León LD, Ayala-Sánchez M, Rosas-Cabral A, Aviña-Zubieta JA, Galindo-Rodríguez G, Vadillo-Buenfil M, Salazar-Exaire D.

Ann Hematol. 2004 May;83(5):295-301. Epub 2003 Dec 5.

PMID:
15060749
[PubMed - indexed for MEDLINE]
12.

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.

DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.

Clin Cancer Res. 2004 Aug 1;10(15):5065-71.

PMID:
15297408
[PubMed - indexed for MEDLINE]
Free Article
13.

Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.

Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E, Cwynarski K, Olavarria E, Yong A, Apperley JF, Goldman JM.

Blood. 2000 Oct 15;96(8):2712-6.

PMID:
11023502
[PubMed - indexed for MEDLINE]
Free Article
14.

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J.

J Clin Oncol. 1997 Feb;15(2):433-44.

PMID:
9053463
[PubMed - indexed for MEDLINE]
Free Article
15.

Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.

Enright H, Davies SM, DeFor T, Shu X, Weisdorf D, Miller W, Ramsay NK, Arthur D, Verfaillie C, Miller J, Kersey J, McGlave P.

Blood. 1996 Jul 15;88(2):714-20.

PMID:
8695820
[PubMed - indexed for MEDLINE]
Free Article
16.

Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.

Chiorean EG, DeFor TE, Weisdorf DJ, Blazar BR, McGlave PB, Burns LJ, Brown C, Miller JS.

Biol Blood Marrow Transplant. 2004 Mar;10(3):171-7.

PMID:
14993882
[PubMed - indexed for MEDLINE]
17.

Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.

Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R.

Transplantation. 2009 Dec 15;88(11):1312-8. doi: 10.1097/TP.0b013e3181bbf382.

PMID:
19996931
[PubMed - indexed for MEDLINE]
18.

Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.

Bär BM, Schattenberg A, Mensink EJ, Geurts Van Kessel A, Smetsers TF, Knops GH, Linders EH, De Witte T.

J Clin Oncol. 1993 Mar;11(3):513-9.

PMID:
8445426
[PubMed - indexed for MEDLINE]
Free Article
19.

Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia.

Gilleece MH, Dazzi F.

Leuk Lymphoma. 2003 Jan;44(1):23-8. Review.

PMID:
12691139
[PubMed - indexed for MEDLINE]
20.

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.

Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF, Schattenberg A, Kolb HJ, Ljungman P, Devergie A, Bacigalupo A, Gomez M, Michallet M, Elmaagacli A, Gratwohl A, Apperley J, Niederwieser D.

Blood. 2002 Jul 15;100(2):397-405.

PMID:
12091328
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk